
Drs Patrick Myers, David Taggart, and Michael Mack discuss the ORBITA trial, focusing on the importance of the sham-control design of the trial, ORBITA's context within previous and upcoming trials, and what the results mean for cardiac surgeons.

Drs Patrick Myers, David Taggart, and Michael Mack discuss the ORBITA trial, focusing on the importance of the sham-control design of the trial, ORBITA's context within previous and upcoming trials, and what the results mean for cardiac surgeons.
New to CTSNet? Sign Up